Q-omics provides the consensus-scored IGLC5 profile across patient tissues and cancer cell-line models. IGLC5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGLC5 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, IGLC5 RNA expression shows 10,694 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where IGLC5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGLC5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGLC5 survival associations across molecular data types. IGLC5 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGLC5 RNA expression–survival associations across cancer types. High IGLC5 expression shows unfavorable associations in ACC, but favorable associations in HNSC, SKCM, LUAD, CESC and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IGLC5 RNA expression.
This table summarizes IGLC5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGLC5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGLC5 shows lower tumor expression in COAD, BRCA, STAD and READ and higher tumor expression in LUAD. The COAD box plot shows higher IGLC5 RNA expression in normal versus tumor tissue (log2 FC = −0.591, t-test p < 0.001).
This table shows molecular features associated with IGLC5 in patient tissues and cancer cell lines. In patient samples, IGLC5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
